or Try an Advanced Search...

    Technical Analysis for EIGR - Eiger BioPharmaceuticals, Inc.

    Grade Last Price % Change Price Change
    F 1.73 -9.21% -0.18
    EIGR closed down 9.21 percent on Wednesday, April 10, 2024, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 9
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical EIGR trend table...
    Date Alert Name Type % Chg
    Narrow Range Bar Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    Calm After Storm Range Contraction -9.21%
    NR7 Range Contraction -9.21%
    Narrow Range Bar Range Contraction -9.21%
    Wide Bands Range Expansion -9.21%
    Oversold Stochastic Weakness -9.21%
    Calm After Storm Range Contraction -18.25%
    Older End-of-Day Signals for EIGR ...

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    EIGR Chart by TradingView
    Basic chart:

    Profile

    Eiger BioPharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops a portfolio of late-stage drugs for orphan diseases. It offers Sarasar, which is used for the treatment of hepatitis delta; Exendin that is used for the treatment of hypoglycemia; and Bestatin, which is used for the treatment of pulmonary arterial hypertension and lymphedema. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is based in Palo Alto, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Hypertension Hepatitis Specialty Drugs Pulmonary Arterial Hypertension Orphan Disease Pulmonary Hypertension Treatment Of Hepatitis Lymphedema Hypoglycemia

    Is EIGR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 4 EIGR, ADXN and BROG are among premarket gainers
    Apr 1 Eiger Biopharmaceuticals Files for Chapter 11 Bankruptcy
    Apr 1 Eiger BioPharmaceuticals Files for Bankruptcy
    Apr 1 Eiger reportedly files for Chapter 11, stock plunges 52%
    Apr 1 Eiger BioPharmaceuticals Files for Voluntary Chapter 11 Protection
    Jan 18 Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan
    Jan 4 Eiger BioPharmaceuticals announces 1-for-30 reverse stock split
    Jan 4 Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split
    Nov 9 Eiger BioPharmaceuticals GAAP EPS of -$0.41, revenue of $3.2M
    Nov 9 Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
    See more EIGR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 43.35
    52 Week Low 1.1
    Average Volume 139,801
    200-Day Moving Average 11.59
    50-Day Moving Average 5.29
    20-Day Moving Average 3.95
    10-Day Moving Average 2.46
    Average True Range 0.84
    RSI (14) 28.57
    ADX 22.97
    +DI 18.90
    -DI 32.38
    Chandelier Exit (Long, 3 ATRs) 4.74
    Chandelier Exit (Short, 3 ATRs) 3.62
    Upper Bollinger Bands 7.50
    Lower Bollinger Band 0.41
    Percent B (%b) 0.19
    BandWidth 179.30
    MACD Line -1.13
    MACD Signal Line -0.90
    MACD Histogram -0.2297
    Fundamentals Value
    Market Cap 2.55 Million
    Num Shares 1.48 Million
    EPS -58.50
    Price-to-Earnings (P/E) Ratio -0.03
    Price-to-Sales 0.62
    Price-to-Book 0.87
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.09
    Resistance 3 (R3) 2.10 2.00 2.03
    Resistance 2 (R2) 2.00 1.91 1.99 2.00
    Resistance 1 (R1) 1.86 1.85 1.81 1.85 1.98
    Pivot Point 1.76 1.76 1.74 1.75 1.76
    Support 1 (S1) 1.62 1.67 1.57 1.61 1.47
    Support 2 (S2) 1.52 1.61 1.51 1.45
    Support 3 (S3) 1.38 1.52 1.43
    Support 4 (S4) 1.37